FOSFOMYCIN RESISTANCE AMONG UROPATHOGENIC ESCHERICHIA COLI ISOLATES WITH EMPHASIS ON ESBL PRODUCTION: A TERTIARY CARE HOSPITAL – BASED STUDY
DOI:
https://doi.org/10.4238/dka4pf91Keywords:
Fosfomycin, Escherichia coli, extended-spectrum β-lactamase, AmpC, urinary tract infection, antimicrobial resistanceAbstract
Background: Fosfomycin is an important oral option for urinary tract infection (UTI) caused by multidrug-resistant (MDR) Enterobacterales, but resistance is emerging and data on its relationship with different β-lactamase phenotypes are limited from India. The present study aimed to determine the prevalence of fosfomycin resistance among clinical isolates of E.coli. Methods: In this cross-sectional study, 383 urinary isolates of Escherichia coli from patients with clinically diagnosed UTI were tested for antimicrobial susceptibility by Kirby–Bauer disk diffusion (CLSI M100, 34th edition). ESBL, AmpC and carbapenemase production were detected phenotypically (double-disk diffusion, combination-disk and modified carbapenem inactivation methods, respectively); blaTEM and blaCTX-M were detected by PCR in 190 isolates. Fosfomycin MIC was determined by agar dilution. Groups were compared using chi-square, Fisher’s exact and Welch t-tests. Results: The mean patient age was 38 ± 16 years; 56.4% were female and 85.9% were in-patients. ESBL, AmpC and carbapenemase production were found in 49.1% (188/383), 33.7% (129/383) and 11.2% (43/383) of isolates, and 63.7% (244/383) were MDR. Among PCR-tested isolates, blaCTX-M and blaTEM were present in 96.8% and 92.1%. Fosfomycin had the lowest resistance of all agents (2.3%, 9/383; 95% CI 1.2–4.4), with MIC50/MIC90 of 0.5/1.0 µg/mL. All nine resistant isolates were ESBL-positive and MDR. Fosfomycin resistance was significantly more frequent in ESBL-positive (4.8% vs 0%; p = 0.0015), AmpC-positive (5.4% vs 0.8%; p = 0.0081) and MDR isolates (3.7% vs 0%; p = 0.029), but not by carbapenemase status, sex or care setting. Conclusion: Fosfomycin retained excellent in vitro activity (≥94.6% susceptibility) against ESBL-, AmpC- and MDR E. coli, although the few resistant isolates were confined to ESBL-producing MDR strains. Continued susceptibility surveillance is warranted to preserve this agent.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

